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In April 2009, the Centers for Disease Control and Prevention
(CDC) reported the ﬁrst two cases of human infection with a novel
inﬂuenza H1N1 virus in the United States (2009a,c) and over the
course of the next several weeks, the virus spread around the world
(WHO, http://www.who.int/csr/don/2009_07_06/en) prompting
the World Health Organization (WHO) to declare a global inﬂuenza
pandemic on June 11, 2009 (WHO, http://www.who.int/csr/disease/
swineﬂu/en).
Antigenic and genetic characterization of the novel inﬂuenza H1N1
virus indicate that the virus contains a unique combination of gene
segments from viruses that had been circulating in pigs in North
American and Europe; 6 of the 8 gene segments (3 polymerase genes,
HA, NP and NS) were derived from a triple reassortant North
American H1N2 swine inﬂuenza virus and the NA and M gene
segments were derived from a Eurasian lineage swine H1N1 virus
(Garten et al., 2009). The 2009 pandemic H1N1 viruses isolated from
human cases are antigenically equivalent to one another and are
similar to North American swine H1N1 viruses, but distinct from
seasonal human inﬂuenza H1N1 viruses (Garten et al., 2009).
The 2009 pandemic H1N1 virus is not the ﬁrst swine-origin H1N1
virus to infect humans. In the past 35 years, more than 50 sporadiccases of swine inﬂuenza virus infection have occurred in humans,
mostly caused by classical swine inﬂuenza viruses (Hay et al., 2001;
Kendal et al., 1977; Myers et al., 2007; Shinde et al., 2009; Thompson
et al., 1976; Webster et al., 1992). Signs and symptoms of infection
with classic swine inﬂuenza virus in humans are often indistinguish-
able from those of infection with human inﬂuenza viruses (Myers et
al., 2007). The most notable instance occurred in 1976, after the
isolation of a swine H1N1 inﬂuenza virus (A/New Jersey/1976) from a
military recruit at Fort Dix, NJ. There were 12 additional cases
identiﬁed by virus isolation or serologic methods and one military
recruit died of the disease (Gaydos et al., 1977; Hodder et al., 1977).
Concerns of the pandemic potential of the A/New Jersey/1976 H1N1
inﬂuenza virus led to the implementation of a mass vaccination
program, which resulted in the administration of ~45 million doses of
inactivated vaccine in the U.S (Dowdle, 1997). The vaccine campaign
was halted because the pandemic did not materialize and adverse
events were reported in association with the vaccine. Since then,
sporadic cases of swine inﬂuenza infection associated with clinical
disease have occurred in people exposed to sick pigs (O'Brien et al.,
1977) and were occasionally fatal (Rota et al., 1989); only limited,
non-sustained human-to-human transmission of swine inﬂuenza
viruses had been reported before April 2009 (Robinson et al., 2007;
Top and Russell, 1977; Wells et al., 1991).
Because the hemagglutinin of the 2009 pandemic H1N1 virus is a
derivative of and is antigenically related to classical swine inﬂuenza
H1N1 viruses, we investigated the ability of swine inﬂuenza viruses to
protect ferrets and mice from challenge with the 2009 pandemic
H1N1 virus. We selected A/California/7/2009 (H1N1) and A/
Fig. 1. Level of replication of H1N1 viruses inmice. Groups of 4mice were inoculated i.n.
with 105 TCID50/50μl of CA/7/09, CA/4/09, NJ/76, and sw/IA/31 viruses. Virus titers in
the nasal turbinates (A), lungs (B), and brains (C) of 4 mice per group sacriﬁced on days
2 (black bars), 3 (open bars), 4 (grey bars), and 7 (hatch bars) p.i., respectively are
expressed as mean±SE log10 TCID50/g of tissue. The dashed horizontal line indicates
the lower limit of detection.
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unrelated cases of febrile respiratory illness in children who resided
in adjacent counties in southern California and were the ﬁrst swine-
origin human 2009 pandemic H1N1 viruses identiﬁed in the United
States (2009a,c). Hemagglutination inhibition (HAI) assays reveal that
the 2009 pandemic H1N1 viruses (A/California/7/2009 and A/
California/4/2009 viruses) are antigenically similar and distinct
from currently circulating seasonal H1N1 viruses (Garten et al.,
2009). The two classical swine inﬂuenza viruses we included in the
study were A/swine/Iowa/1931 (H1N1), a reference classical swine
H1N1 virus closely related to the ﬁrst isolate A/swine/Iowa/15/1930
and A/New Jersey/8/1976 (H1N1), an isolate from the limited
outbreak in 1976 in Fort Dix, NJ. This comparison was made to gain
insight into the degree of protective immunity that may be conferred
by prior infection with inﬂuenza viruses that were derived from pigs
or were antigenically related to swine inﬂuenza viruses.
Results
We ﬁrst established the kinetics of replication and pathogenesis of
the 2009 swine-origin pandemic H1N1 inﬂuenza viruses (CA/7/09
and CA/4/09) and two classical swine inﬂuenza viruses (sw/IW/31
and NJ/76) in mice and ferrets and then used these models to assess
the extent of homologous and heterologous protection provided by
these H1N1 viruses.
Level of viral replication in mice
The kinetics of replication of the H1N1 inﬂuenza viruses are
displayed in Fig. 1. With the exception of the NJ/76 virus, all of the
H1N1 viruses replicated to high titer in the upper respiratory tract
with the sw/IA/31 being the highest (Fig. 1A). In the upper
respiratory tract, mean peak titers on day 3 p.i. of 105, 104.9, 103.3
and 106.4 TCID50/g were observed in mice inoculated with the CA/7/
09, CA/4/09, NJ/76 and sw/IA/31 viruses, respectively. All of the
H1N1 viruses replicated to high titer in the lower respiratory tract of
mice (Fig. 1B); peak titers achieved following inoculation of the
viruses were as follows: 107.4 TCID50/g on day 2 p.i. in mice inoculated
with CA/7/09; 106.7 TCID50/g on day 4 p.i. following inoculation of
CA/4/09; 107.3 TCID50/g on day 2 p.i. following inoculation of NJ/76;
and 108.0 TCID50/g on day 2 p.i. in mice inoculated with sw/IA/
31virus. Virus was detected in the brain of mice infected with CA/7/
09 and CA/4/09 on day 2 p.i. at mean titers of 101.75 and 101.9 TCID50/
g, respectively (Fig. 1C). We cannot conclude deﬁnitively that the
2009 swine-origin pandemic H1N1 inﬂuenza viruses (CA/7/09 and
CA/4/09) spread to the brain of mice because olfactory bulbs were
harvested along with the brain and it is possible that the detection of
virus in these samples may represent direct infection from the nasal
cavity rather than disseminated or systemic spread. Virus was not
detected in the brain of mice that received the NJ/76 virus. Although
virus was not detected in the brain of mice that were infectedwith the
low dose (10 TCID50) of sw/IA/31 (data not shown), virus was
detected in the brain of mice that received a higher dose (105 TCID50)
of sw/IA/31, at mean titers of 101.9, 102.4 and 102 TCID50/g on days 2,
3 and 4 p.i., respectively (Fig. 1C). The presence of virus at three time
points following infection indicate that sw/IA/31 virus is capable of
neuroinvasion and replication in the central nervous system.
Clinical illness and level of viral replication in ferrets
None of the viruses caused lethargy, sneezing, rufﬂed fur,
decreased interest in food, or nasal discharge in ferrets and weight
loss was not observed (Fig. 2A). A slight increase in body temperature
was detected on day 3 especially with sw/IA/31 infection, however
the temperatures remained within the normal range for ferrets
(Fig. 2B). Both the 2009 H1N1 viruses (CA/7/09 and CA/4/09) andthe classical swine H1N1 viruses (sw/IA/31 and NJ/76) replicated to
high titers in the upper respiratory tract of ferrets on 1, 3, and 5 days p.
i. (Fig. 2C). With the exception of the NJ/76 virus, all of the H1N1
viruses replicated to high titers in the lower respiratory tract
(Fig. 2D); peak replication of the CA/7/09 virus was detected on
day 3 and CA/4/09 and sw/IA/31 viruses on day 5 p.i. The peak titer of
the NJ/76 virus was statistically signiﬁcantly lower than the other
H1N1 viruses (pb0.05, Kruskal–Wallis). Virus was not detected in the
brain of ferrets inoculated with these viruses (data not shown).
Effect of prior infection with H1N1 viruses on subsequent challenge with
CA/7/09 virus in mice
In order to assess the extent of homologous and heterologous
protection provided by these antigenically related viruses, we
evaluated the effect of prior infection with 2009 pandemic H1N1
viruses (CA/7/09 and CA/4/09) or classical swine inﬂuenza viruses
(NJ/76 and sw/IW/31) on subsequent challenge with the CA/7/09
virus. Following primary infection with H1N1 viruses, serum
neutralizing antibody titers against the CA/7/09 virus and classical
Fig. 2. Evaluation of clinical signs and viral replication following inoculation of H1N1 viruses in ferrets. Groups of 3 ferrets were inoculated i.n. with 106 TCID50/0.2ml of H1N1 CA/7/
09 (●), CA/4/09 (*), NJ/76 (□), sw/IA/31(◊) viruses. Mock-infected ferrets (▲) received L-15. Percentage change in body weight (A) and average body temperature (B) following i.
n. inoculation of each indicated virus weremonitored daily for 14 days in ferrets. Virus titers in the nasal turbinates (C) and lungs (D) of 3 ferrets per group sacriﬁced on days 1 (black
bars), 3 (open bars), and 5 (grey bars) p.i., respectively are expressed as mean±SE log10 TCID50/g of tissue. The dashed horizontal line indicates the lower limit of detection.
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collected on day 25 post-inoculation (Table 1) and the extent of
replication of the CA/7/09 challenge virus is presented in Fig. 3. Six of
the eight mice inoculated with the CA/7/09 virus as the primary
infection were euthanized between days 7 and 10 post-inoculation
due to severe weight loss and only two mice in the group survived
long enough for challenge; subsequent studies (data not shown)
indicate that these mice received a dose that was approximately the
LD50 of the CA/7/09 virus (104.7 TCID50). Serologic analysis was
therefore limited to the sera from the two survivingmice. Because CA/
7/09 and CA/4/09 viruses are antigenically similar, we used the CA/
7/09 virus for serologic assays. Primary infection with each of the
H1N1 viruses elicited a modest to robust homologous antibodyTable 1
Serum neutralizing antibodies elicited in mice following intranasal infection with H1N1 vir
Primary
infectiona
Serum neutralizing antibod
CA/7/09 NJ/76
GMT (range)b # with detectable antibody/totalc GMT (range) # w
CA/7/09 1280d 2/2 NDe
CA/4/09 446 (320–806) 8/8 NDe
NJ/76 34 (10–63) 7/8 58 (20–113) 8/8
sw/IA/31 41 (10–101) 7/8 29 (16–57) 8/8
a Mice received 105 TCID50 of indicated virus i.n. and serum was obtained on day 25 p.i.
b Values represent geometric mean antibody titers from 2-8 mice per group. Antibodies
undetectable serum neutralizing antibody titer was assigned a value of 10.
c Numbers of mice elicited neutralizing antibody response from each group are indicated
d Serum neutralizing antibody titer in two of the eight mice in the group that survived f
e ND: not determined.response in 100% of the mice (Table 1, titers in bold). The NJ/76 virus
induced a lower homologous neutralizing antibody response than the
other H1N1 viruses, though the virus replicated to comparable titers
in the lungs of mice. Primary infection with CA/7/09 and CA/4/09
viruses provided complete protection from subsequent homologous
challenge in both the upper and lower respiratory tract of mice
(Fig. 3A and B). Primary infection with NJ/76 and sw/IA/31 viruses
elicited low titers of cross-neutralizing antibody against the CA/7/09
virus in 7 of 8 mice. Consistent with the low homologous neutralizing
antibody response, the NJ/76 virus induced a lower titer of cross-
neutralizing antibody response than the sw/IA/31 virus. Although the
level of cross-neutralizing antibody was low, primary infection with
sw/IA/31 virus conferred signiﬁcant protection from CA/7/09 virususes.
y response against indicated virus
sw/IA/31
ith detectable antibody/total GMT (range) # with detectable antibody/total
NDe
NDe
16 (10–25) 3/8
281 (202–403) 8/8
were not detectable in pre-infection sera. Homologous antibody titers are in bold. An
.
ollowing primary infection with CA/7/09.
Fig. 3. Effect of prior infection with H1N1 viruses on subsequent challenge with CA/7/
09 virus in mice. Groups of 4mice were inoculated i.n. with 105 TCID50/50μl of CA/7/09
(horizontal hatch bars), CA/4/09 (grey bars), NJ/76 (diagonal hatch bars), and sw/IA/
31 (open bars) viruses. Mock-infected mice (black bars) received L-15. On day 28 p.i.,
the mice were challenged with 105 TCID50/50μl of CA/7/09 virus. Virus titers in the
nasal turbinates (A) and lungs (B) of 4 mice per group sacriﬁced on 2 and 4 days post-
challenge are expressed as mean±SE log10TCID50/g of tissue. The dashed horizontal
line indicates the lower limit of detection.
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challenge (Fig. 3A) (pb0.05 Kruskal–Wallis, compared with mock-
infected animals) and NJ/76 virus infection resulted in a reduction in
virus titer compared with mock-infected mice, though the difference
did not achieve statistical signiﬁcance. In the lower respiratory tract,
primary infection with sw/IA/31 and NJ/76 viruses conferred partial
protection; the reduction in titer was statistically signiﬁcant for sw/
IA/31 compared with mock-infected animals (pb0.05, Kruskal–
Wallis) (Fig. 3B).
Effect of prior infection with H1N1 viruses on subsequent challenge with
the CA/7/09 virus in ferrets
The extent of homologous and heterologous protection provided
by antigenically related H1N1 viruses was also evaluated in ferrets.
Primary infection with the H1N1 viruses induced robust homologous
HAI and neutralizing antibody responses (Table 2, titers in bold). The
CA/7/09, CA/4/09 and NJ/76 viruses induced robust HAI and
neutralizing antibodies against the CA/7/09 and NJ/76 viruses butTable 2
Serum neutralizing and HAI antibodies elicited in ferrets following intranasal infection with
Primary
infectiona
Geometric mean (range) serum neutralizing antibody titers against
virusb
CA/7/09 NJ/76 sw/IA/31
CA/7/09 1140 (254–5120) 2560 (2032–3225) 10
CA/4/09 2370 (1810–4064) 941 (508–1613) 10
NJ/76 436 (320–806) 2463 (1613–3620) 10
sw/IA/31 37 (32–40) 1881 (1016–4064) 1280 (101
a Ferrets received 106 TCID50 of the virus i.n. and serumwas obtained 4weeks later. Values
not detectable in pre-infection sera. Homologous antibody titers are in bold. Ranges of anti
b An undetectable serum neutralizing antibody titer was assigned a value of 10.
c An undetectable HAI antibody titer was assigned a value of 5.none induced cross-reactive antibodies against sw/IA/31. The sw/IA/
31 virus elicited low titers of cross-neutralizing antibodies against the
CA/7/09 pandemic H1N1 virus (Table 2) and a cross-HAI antibody
responsewas detected in 1 of 3 animals. These data indicated that sw/
IA/31 was antigenically distinct from the 2009 pandemic H1N1 virus.
The signiﬁcance of cross-HAI and cross-neutralizing antibody titers
that exceed homologous titers is unknown. Primary infection with
each of the H1N1 viruses, including sw/IA/31 provided robust
protection from replication of the CA/7/09 virus in the respiratory
tract of ferrets; the titer of the challenge virus was below the limit of
detection when assayed on day 5 post-challenge. The titer of the
challenge virus was measured on day 5 post-challenge because virus
titers in the lungs of ferrets on day 5 were similar to titers achieved on
day 3 (Fig. 2D). The titer of the challenge virus in the lungs and nasal
turbinates of mock-infected animals was 107.5 TCID50/g and 107.8
TCID50/g, respectively and the absence of detectable virus in the other
groups was statistically signiﬁcant (pb0.05, Mann–Whitney U test).
Discussion
In order to better understand the pathogenesis of the swine-origin
pandemic 2009 H1N1 virus, several investigators have compared
these viruses with seasonal inﬂuenza viruses. However, CA/7/09, the
virus recommended by the WHO as the reference virus for vaccine
development, has not been evaluated extensively in animal models.
We evaluated the ability of this virus to cause disease in mice and
ferrets and compared it with CA/4/09 (H1N1) as well as a progenitor
classical swine H1N1 virus, sw/IA/31, and NJ/76, a swine inﬂuenza
virus that caused a limited outbreak of human infections at a military
camp in 1976. We used egg grown viruses, as have other investigators
(Maines et al., 2009; Munster et al., 2009). Our goal was to establish
the kinetics of replication in these models so that we could evaluate
the extent of cross-protection conferred by classical swine H1N1
viruses against the 2009 pandemic H1N1 virus.
Consistent with ﬁndings of other investigators (Itoh et al., 2009;
Maines et al., 2009), we observed that the pandemic 2009 H1N1
inﬂuenza viruses (CA/7/09 and CA/4/09) replicated efﬁciently in the
respiratory tract of mice without prior host adaptation. Statistically
signiﬁcant differences were not observed in the replication kinetics of
the 2009 pandemic and classical swine H1N1 viruses in either the
upper or lower respiratory tract of mice. The replication kinetics and
pathogenicity of the swine-origin pandemic 2009 H1N1 viruses in
ferrets in our study were also consistent with ﬁndings of others (Itoh
et al., 2009; Maines et al., 2009; Munster et al., 2009). However, the
replication of the pandemic H1N1 inﬂuenza viruses in ferrets was not
associated with signiﬁcant signs or symptoms of illness in our
experiments. In our study, female and male ferrets aged 8–12 weeks
were inoculated intranasally with 106 TCID50 of virus in a volume of
0.2 mL while other investigators who infected older ferrets with a
larger inoculum reported clinical illness (Maines et al., 2009). We
used a smaller volume of inoculum because we have previously
shown that intranasal administration of virus in larger volumeH1N1 viruses.
indicated Geometric mean (range) serumHAI antibody titers against indicated
virusc
CA/7/09 NJ/76 sw/IA/31
320 113 (80–160) 5
403 (320–640) 80 (40–160) 5
80 (40–160) 127 (80–160) 5
6–2032) 8 (5–20) 64 (40–160) 101 (40–320)
represent geometric mean antibody titers from three ferrets per group. Antibodies were
body titers are in parentheses.
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absence of signiﬁcant local replication of the inoculated virus (Jin
et al., 2007).
In both mice and ferrets, the pandemic 2009 H1N1 inﬂuenza
viruses induced a robust homologous antibody response. Although
NJ/76 and sw/IA/31 viruses are antigenically different from the CA/
7/09 virus (Garten et al., 2009), primary infection with the classical
swine H1N1 viruses provided partial protection from subsequent
challenge with the CA/7/09 virus in mice. Despite the relatively low
degree of amino acid sequence homology between the HAs of the
pandemic 2009 H1N1 viruses and the classical swine viruses (CA/7/
09 vs. NJ/76 and sw/IA/31 91% and 90%, respectively), primary
infection with the classical swine H1N1 viruses elicited some cross-
reactive neutralizing activity and provided robust protection from
subsequent challenge with the CA/7/09 virus in ferrets. Primary
infection with inﬂuenza viruses stimulates mucosal and systemic
antibodies as well as cellular immune responses and these responses
contribute to protection. However, our analysis was limited to serum
antibody responses, which are the most well established correlate of
protection. The difference in the level of cross-protection conferred by
the swine inﬂuenza viruses in mice and ferrets in our study are
consistent with the level of cross-reactive antibodies induced in the
two species; higher titers of cross reactive antibodies were induced in
ferrets associated with robust protection from challenge while lower
titers of cross reactive antibodies in mice were associated with partial
protection. Our ﬁndings are consistent with the observations of
Manicassamy et al., 2010 and Kash et al., 2010 who found that
antibodies elicited against 1918-like or classical swine H1N1 vaccines
fully protect mice from lethal challenge with the 2009 pandemic
H1N1 virus.
A proportion of people, especially older individuals, have anti-
bodies that cross-react with the 2009 pandemic H1N1 virus (2009b;
Greenberg et al., 2009; Hancock et al., 2009; Itoh et al., 2009; Kash et
al., 2010; McCullers et al., 2010); these individuals were likely
exposed to H1N1 viruses that were more closely related to classical
swine H1N1 inﬂuenza viruses than recent seasonal H1N1 viruses are.
The epidemiology of the 2009 H1N1 pandemic shows that the elderly
are less affected by severe morbidity and mortality (Chowell et al.,
2009), suggesting that they are protected from severe disease by
cross-reactive immunity. Sera from a small sample of individuals who
had received the swine ﬂu vaccine in 1976 had cross-reactive
antibodies to the 2009 H1N1 virus (Hancock et al., 2009). Our
ﬁndings in animal models support these observations and suggest
that the elderly and the ~45 million people who had prior infection
with classical swine inﬂuenza virus and who received the swine ﬂu
vaccine in 1976 would be protected from severe disease caused by the
pandemic 2009 H1N1 inﬂuenza viruses (CA/7/09).
Materials and methods
Viruses
The swine-origin 2009 H1N1 viruses, A/California/7/2009 (CA/7/
09) and A/California/4/2009 (CA/4/09) used in this study were
kindly provided by Drs. Ruben Donis and Alexander Klimov from the
Inﬂuenza Division, Centers for Disease Control and Prevention,
Atlanta, GA. The A/swine/Iowa/1931 (sw/IA/31) (H1N1) and A/
New Jersey/8/1976 (NJ/76) (H1N1) viruses were kindly provided by
Drs. Jeffery Taubenberger and Brian Murphy, respectively, from the
National Institutes of Health, Bethesda, MD.
The CA/4/09 virus was ampliﬁed in Madin-Darby canine kidney
(MDCK) cells and the other viruses were propagated in the allantoic
cavity of 9 to 11-day old embryonated speciﬁc pathogen-free (SPF)
hen's eggs (Charles River, Wilmington, MA), incubated at 37 °C,
harvested 48 h post-inoculation and tested for hemagglutinating
activity. Infectious allantoic ﬂuids were pooled, divided into aliquotsand stored at −80 °C until use. The ﬁfty percent tissue culture
infectious dose (TCID50) for each virus was determined by serial
titration of virus in MDCK cells and calculated by the method
developed by Reed and Muench (1938).
Animal experiments were approved by the National Institutes of
Health Animal Care and Use Committee.Evaluation of viral replication in the respiratory tract of mice and
antibody response to the H1N1 viruses in mice
Level of replication. To evaluate the level of replication of the viruses
in the respiratory tract of mice, we administered 50μl containing 105
TCID50 of each of the H1N1 viruses or 50μl of Leibovitz-15 (L-15,
Invitrogen-GIBCO) intranasally (i.n.) to 4- to 6-week-old female
BALB/c mice (Taconic Farms, Inc., Germantown, NY) lightly anesthe-
tized with isoﬂurane. Based on previous data (Memoli et al., 2009)
establishing the lethality of sw/IA/31 for mice, one group of mice also
received 50 μl of 10 TCID50 of sw/IA/31. On days 2, 3, 4 and 7
following inoculation, lungs, nasal turbinates and brains (including
olfactory bulbs) were harvested from 4 mice in each group. In the
mice that received 105 TCID50 of sw/IA/31, tissues were harvested on
days 2, 3 and 4 following inoculation; in mice that received 10 TCID50
of sw/IA/31, tissues were harvested on days 2, 4 and 7 following
inoculation. Organs were weighed and homogenized in L-15 medium
(Invitrogen-GIBCO) containing antibiotic–antimycotic (penicillin,
streptomycin, and amphotericin B) (Invitrogen-GIBCO) to make 5%
(wt/vol) (nasal turbinates) or 10% (wt/vol) (lungs, brains) tissue
homogenates. Tissue homogenates were clariﬁed by centrifugation
and titrated in 24- and 96-well tissue culture plates containing MDCK
cell monolayers and TCID50 was calculated by the method developed
by Reed andMunch (Reed andMuench, 1938). Titers are expressed as
log10 TCID50/g of tissue.Evaluation of antibody response. Neutralizing antibody titers in pre
and post-infection (p.i.) sera were determined in a microneutraliza-
tion (MN) assay as described earlier (Joseph et al., 2008). Serial two-
fold dilutions of serum were prepared starting from a 1:10 or 1:20
dilution following receptor destroying enzyme (RDE) treatment and
heat-inactivation. Equal volumes of serum and virus were mixed and
incubated for 60 min at room temperature. The residual infectivity of
the virus–serum mixture was determined in MDCK cells in four
replicates for each dilution. Neutralizing antibody titers were deﬁned
as the reciprocal of the highest dilution of serum that completely
neutralized the infectivity of 100 TCID50 of the virus as determined by
the absence of CPE at day 4, as previously described (Joseph et al.,
2008). The small volume of mouse sera precluded testing in a
hemagglutination inhibition (HAI) assay.Evaluation of viral replication and antibody response to H1N1 viruses in
ferretsLevel of replication. The ability of H1N1 viruses to replicate in ferrets
was compared in groups of 8- to 12-week-old ferrets (Triple F Farms,
Sayre, PA) that were seronegative to seasonal H3N2, H1N1 and swine-
origin 2009 H1N1 viruses. Each ferret was lightly anesthetized with
isoﬂurane and inoculated i.n. with 106 TCID50 of each of the H1N1
viruses in a volume of 0.2 mL (0.1 mL per nostril). On days 1, 2, and 3
post-inoculation, groups of three ferrets were euthanized and nasal
turbinates, left lower lobe of the lung, and portions from the anterior,
middle and posterior part of the brain were harvested and 10% w/v
tissue homogenates were titrated onMDCKmonolayers, as previously
described (Joseph et al., 2008). Titers are expressed as log10 TCID50/g
of tissue.
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were infected i.n. with each of the H1N1 viruses to evaluate symptoms/
clinical signs and antibody responses to the H1N1 viruses. The infected
animals were monitored daily for 14 days for clinical signs of inﬂuenza
infection, body temperature and weight. Ferrets were evaluated for
nasal symptoms including nasal rattling, sneezing, nasal discharge, and
mouth breathing and level of activity (Reuman et al., 1989).
Evaluation of antibody response. Serum samples collected prior to
dosing and on days 14 and 28 p.i. were tested for HAI antibodies by
standard methods using 4 HA units of virus in V-bottom 96-well
microtiter plates with 0.5% turkey erythrocytes. Neutralizing antibody
titers were also evaluated in a microneutralization assay, as described
above.
Cross protection studies in mice
Groups of four 6- to 8-week-old BALB/c mice (Taconic Farms, Inc.,
Germantown, NY) were infected with 50 μl containing 105 TCID50 of
H1N1 viruses or L-15 medium (mock-infected) and were challenged
with 50 μl containing 105 TCID50 of the CA/7/09 virus i.n. 27 days
later. The nasal turbinates, lungs, and brain tissue were harvested
from these mice at days 2 and 4 following challenge and were
homogenized and virus titers were determined in MDCK cells.
Cross protection studies in ferrets
Groups of three 8- to 12-week-old ferrets infected with 106 TCID50
of H1N1 viruses or L-15 medium (mock-infected) were challenged
with 105 TCID50 of the CA/7/09 virus i.n. 28 days later. The nasal
turbinates, lungs, and brain tissue were harvested from these ferrets
5 days following challenge and were homogenized and virus titers
were determined in MDCK cells. We selected this time point for
harvest of tissues because the difference in titer on days 3 and 5 was
not statistically signiﬁcant and day 5 was a later time point.
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